Corline Biomedical Q2: Initial take – Sales a bit soft, but no major surprises overall - Redeye

Redeye provides an initial take following the release of Corline’s Q2 2025 report. As expected, this was not a quarter characterised by strong sales. The quarterly sales came in slightly below our projection, while costs were broadly in line. We will shortly publish a research update, where we anticipate making minor downward adjustments to our near-term sales estimates. That said, we do not foresee any material impact on Corline's valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1124968/corline-biomedical-q2-initial-take-sales-a-bit-soft-but-no-major-surprises-overall?utm_source=finwire&utm_medium=RSS